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to the A&C regimen. Tumors were resected prior to drug treatment and 
their RNAs analyzed using the microarray Affymetrix platforms fol-
lowed by the unsupervised cluster analysis. Genes-discriminators were 
then validated by RT-PCR on tumor and normal tissue-matched clinical 
samples. 
Results. We found a clear segregation of drug responsive vs. drug 
resistant patients based on the analysis of differentially expressed 
genes. SLC39A8, PMCA1, and PLCB1 were identiﬁed as the most 
robust discriminators of these two groups with higher expression levels 
in the drug-sensitive cohort. SLC39A8 encodes a zinc, cadmium (and, 
possibly, platinum) inﬂux transporter that may sensitize the cell to 
cisplatin effect. PMCA1 (ATP2B1) is a member of the P-type family of 
primary ion transport ATPases involved in the maintenance of intracel-
lular calcium homeostasis, while PLCB1 is a phosphoinositide-speciﬁc 
phospholipase that uses calcium as a cofactor and plays an important 
role in the intracellular transduction of extracellular signals. The last 
two aforementioned genes are most likely involved in the apoptotic 
pathways, and may facilitate, in particular, cancer cell death upon drug 
treatment. Expression of these three genes showed a remarkable cor-
relation in tumor and matched normal samples suggesting involvement 
in the same cellular process.
Conclusions: Our data link SLC39A8, PMCA1, and PLCB1 expres-
sion with the sensitivity of mesothelioma to pemetrexed and cisplatin. 
Studies on overexpressed or silenced SLC39A8, PMCA1 and PLCB1 
are underway to further investigate their roles in the innate resistance to 
these and other drugs. The ﬁnal goal of this study is developing a tool 
to sensitize cancer cells prior to drugs administration to ensure more 
effective and speciﬁc chemotherapy. 
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Background: A recently completed phase III study demonstrated that 
pemetrexed plus cisplatin (PC) had similar efﬁcacy and better tolerability 
than gemcitabine plus cisplatin (GC) in 1725 chemonaive patients with 
advanced NSCLC. As part of this phase III trial, we quantiﬁed mRNA 
and protein levels in pretreatment biopsies to identify biomarkers that 
may predict the clinical outcome of patients treated with PC or GC.
Methods: Chemonaive patients with stage IIIB or IV NSCLC were 
randomly assigned to receive up to 6 cycles of PC (pemetrexed 500 
mg/m2 plus cisplatin 75 mg/m2 on day 1) or GC (gemcitabine 1250 
mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1). Both arms 
received folic acid and vitamin B12 supplementation. More than 200 
formalin-ﬁxed parafﬁn-embedded tissue samples were available for 
gene expression and immunohistochemistry (IHC) analyses. We se-
lected markers involved in the drug pathway or with pathways targeted 
by other NSCLC treatments. These markers included thymidylate 
synthase (TS) for pemetrexed, ribonucleotide reductase M1 (RRM1) 
for gemcitabine, excision repair cross-complementing 1 (ERCC1) for 
cisplatin, and epidermal growth factor receptor (EGFR) for EGFR 
tyrosine kinase inhibitors.
Results: Of 232 patients with tissue samples, 69 had gene expres-
sion results and 181 had IHC results. Treatment-related differences in 
clinical outcomes were not consistently associated with pretreatment 
biomarker expression for the 9 genes evaluated. However, high EGFR 
expression was associated with improved clinical outcomes indepen-
dent of treatment. When patients were categorized into binary expres-
sion groups (“high” and “low” pretreatment mRNA expression), high 
EGFR was associated with improved progression-free survival (PFS) 
and time to progressive disease (TtPD) regardless of treatment (PFS 
HR = 0.344, 95% CI 0.19-0.63, p = 0.009; TtPD HR = 0.404, 95% 
CI 0.22-0.76, p = 0.049). Several analyses showed weak associations 
between TS expression and clinical outcomes. A statistically signiﬁ-
cant interaction between TS expression level and treatment effect (p 
= 0.014) was identiﬁed for TtPD. Speciﬁcally, a per-unit change in 
relative gene expression (Δ CT), equal to a doubling in TS gene copy 
number, predicted a 25% increase in hazard of tumor progression for 
PC patients and a 38% decrease in hazard for GC patients.
Conclusions: High levels of EGFR gene expression appear to predict 
better clinical outcomes in chemonaive patients with stage IIIB/IV 
NSCLC. Our results also suggest a potential association between low 
TS expression and improved outcomes with PC. Larger translational 
research studies are needed to determine the prognostic or predictive 
value of these biomarkers.
C6-02 Cancer Genetics, Wed, 10:30 - 12:15
Prospective study assessing MDM2 309 and p53 Arg72Pro single 
nucleotide polymorphism (SNPs) and clinical outcome in advanced 
lung cancer
Mandrile, Giorgia1 Giachino, Daniela F.1 Novello, Silvia2 Ghio, Paolo2 
Selvaggi, Giovanni2 Gregori, Dario3 De Marchi, Mario1 Scagliotti, 
Giorgio V.2 
1 Medical Genetics Unit, University of Torino, Orbassano, Italy 2 Tho-
racic Oncology Unit, Department of Clinical & Biological Sciences, 
University of Torino, Orbassano, Italy 3 Medical Statistics, Department 
of Public Health, University of Torino, Orbassano, Italy 
Background: After DNA damage, the p53Arg allele of the Arg72Pro 
SNP (rs1042522:C>G) has a higher pro-apoptotic activity, while the 
p53Pro allele more efﬁciently induces cell cycle arrest. The G allele of 
the MDM2 SNP309 (rs2279744:T>G) expresses higher levels of the 
protein thus attenuating the p53 pathway. Both SNPs have been shown 
to affect lung cancer risk. We aimed to investigate their relationship 
with the clinical outcome of chemotherapy.
Methods: We prospectively recruited 426 consecutive patients with 
advanced disease (352 NSCLC and 74 SCLC, 57% metastatic) referred 
